BillionToOne to Report Q1 2026 Earnings on May 6

The molecular diagnostics company will host a conference call to discuss its financial results.

Apr. 15, 2026 at 12:05pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, precision-engineered molecular diagnostics equipment, with dramatic shadows and highlights accentuating the complex, powerful nature of the technology.BillionToOne's advanced molecular diagnostics equipment, the backbone of its innovative testing solutions, will be a key focus of the company's upcoming earnings report.Menlo Park Today

BillionToOne, Inc., a next-generation molecular diagnostics company, announced that it will release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. The company will host a conference call to discuss the results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

Why it matters

As a growing player in the molecular diagnostics space, BillionToOne's quarterly earnings report will provide insights into the company's financial performance and growth trajectory. The earnings call will also give investors and analysts an opportunity to better understand the company's business strategy and market positioning.

The details

BillionToOne, headquartered in Menlo Park, California, develops molecular diagnostics tests using its patented Quantitative Counting Templates™ (QCT™) technology. The company's Q1 2026 earnings report will cover its financial results for the three-month period ending March 31, 2026. Analysts planning to participate in the conference call must register in advance.

  • BillionToOne will release its Q1 2026 financial results after the market close on Wednesday, May 6, 2026.
  • The company will host a conference call to discuss the results at 1:30pm Pacific Time / 4:30pm Eastern Time on May 6, 2026.

The players

BillionToOne, Inc.

A next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Got photos? Submit your photos here. ›

What’s next

Analysts and investors will be able to access a live and archived webcast of the earnings call on BillionToOne's investor relations website.

The takeaway

BillionToOne's upcoming earnings report will provide valuable insights into the company's financial performance and growth strategy as it continues to develop innovative molecular diagnostics technologies.